BioMerieux Gross Profit 2017-2024 | BMXMF
BioMerieux annual/quarterly gross profit history and growth rate from 2017 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- BioMerieux gross profit for the quarter ending June 30, 2024 was $M, a NAN% increase year-over-year.
- BioMerieux gross profit for the twelve months ending June 30, 2024 was $0M, a NAN% increase year-over-year.
- BioMerieux annual gross profit for 2023 was $2.227B, a 5.21% increase from 2022.
- BioMerieux annual gross profit for 2022 was $2.116B, a 8.91% decline from 2021.
- BioMerieux annual gross profit for 2021 was $2.323B, a 15.97% increase from 2020.
| BioMerieux Annual Gross Profit (Millions of US $) |
|
|---|---|
| 2023 | $2,227 |
| 2022 | $2,116 |
| 2021 | $2,323 |
| 2020 | $2,003 |
| 2019 | $1,643 |
| 2018 | $1,538 |
| 2017 | $1,370 |
| 2016 | $1,218 |
| 2015 | $ |
| BioMerieux Quarterly Gross Profit (Millions of US $) |
|
|---|---|
| 2024-06-30 | |
| 2023-12-31 | |
| 2023-06-30 | |
| 2022-12-31 | |
| 2022-06-30 | |
| 2021-12-31 | |
| 2021-06-30 | |
| 2020-12-31 | |
| 2019-12-31 | |
| 2019-06-30 | |
| 2018-12-31 | |
| 2018-06-30 | |
| 2017-12-31 | |
| 2017-06-30 | |
| 2016-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $14.914B | $4.307B |
| bioM?rieux S.A. designs, develops, manufactures and markets systems in the field of vitro diagnostics. The company provides diagnostic solutions which determine the source of disease and contamination. It also offers solutions for managing infectious diseases, cancers and cardiovascular diseases in clinical applications. The company provides solutions for the enumeration of microbial flora, detection of specific pathogenic bacteria, monitoring of air and surface quality and sterility testing for the agri-food, cosmetics and pharmaceutical industries. bioM?rieux S.A. is based in Marcy L Etoile, France. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $146.516B | 27.37 |
| Elevance Health (ELV) | United States | $98.469B | 13.19 |
| CVS Health (CVS) | United States | $85.419B | 12.50 |
| Cencora (COR) | United States | $53.926B | 19.57 |
| DiDi Global (DIDIY) | China | $23.525B | 0.00 |
| Natera (NTRA) | United States | $19.117B | 0.00 |
| ICON (ICLR) | Ireland | $14.132B | 12.84 |
| Solventum (SOLV) | United States | $13.154B | 12.27 |
| Revvity (RVTY) | United States | $12.712B | 21.59 |
| Avantor (AVTR) | United States | $11.045B | 16.21 |
| CochLear (CHEOY) | Australia | $10.877B | 0.00 |
| Doximity (DOCS) | United States | $10.834B | 56.34 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $10.609B | 0.00 |
| Viatris (VTRS) | United States | $10.397B | 3.29 |
| Medpace Holdings (MEDP) | United States | $9.283B | 24.12 |
| Sonic Healthcare (SKHHY) | Australia | $7.768B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.697B | 14.59 |
| HealthEquity (HQY) | United States | $7.644B | 37.60 |
| Bausch + Lomb (BLCO) | Canada | $5.111B | 23.39 |
| Amplifon S.p.A (AMFPF) | Italy | $4.961B | 26.19 |
| Organon (OGN) | United States | $3.841B | 3.91 |
| Alignment Healthcare (ALHC) | United States | $3.572B | 0.00 |
| Sotera Health (SHC) | United States | $3.305B | 19.11 |
| BrightSpring Health Services (BTSG) | United States | $3.165B | 32.89 |
| Surgery Partners (SGRY) | United States | $3.031B | 34.93 |
| Concentras Parent (CON) | United States | $2.781B | 14.47 |
| GeneDx Holdings (WGS) | United States | $2.486B | 295.22 |
| Ardent Health Partners (ARDT) | United States | $1.963B | 0.00 |
| Progyny (PGNY) | United States | $1.908B | 42.15 |
| Agilon Health (AGL) | United States | $1.785B | 0.00 |
| Premier (PINC) | United States | $1.760B | 11.27 |
| PACS (PACS) | United States | $1.713B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.692B | 36.75 |
| Teladoc Health (TDOC) | United States | $1.382B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.243B | 10.42 |
| Establishment Labs Holdings (ESTA) | $1.177B | 0.00 | |
| Ryman Healthcare (RYHTY) | New Zealand | $1.031B | 0.00 |
| CareDx (CDNA) | United States | $0.984B | 16.75 |
| AMN Healthcare Services Inc (AMN) | United States | $0.934B | 7.39 |
| Embecta (EMBC) | United States | $0.741B | 5.08 |
| QDM (QDMI) | Hong Kong, SAR China | $0.526B | 13.77 |
| Auna S.A (AUNA) | Luxembourg | $0.526B | 13.94 |
| Enhabit (EHAB) | United States | $0.444B | 41.86 |
| Sonida Senior Living (SNDA) | United States | $0.441B | 0.00 |
| InnovAge Holding (INNV) | United States | $0.403B | 0.00 |
| SBC Medicals (SBC) | United States | $0.329B | 0.00 |
| DocGo (DCGO) | United States | $0.269B | 11.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.265B | 0.00 |
| Nutex Health (NUTX) | United States | $0.256B | 5.10 |
| LifeMD (LFMD) | United States | $0.243B | 0.00 |
| Performant Healthcare (PHLT) | United States | $0.232B | 0.00 |
| Beauty Health (SKIN) | United States | $0.168B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.139B | 0.00 |
| So-Young (SY) | China | $0.098B | 0.00 |
| Biodesix (BDSX) | United States | $0.091B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.090B | 0.00 |
| OncoCyte (OCX) | United States | $0.088B | 0.00 |
| Oncology Institute (TOI) | United States | $0.086B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.075B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.065B | 0.00 |
| NeueHealth (NEUE) | United States | $0.056B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.026B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.024B | 0.00 |
| ModivCare (MODV) | United States | $0.019B | 6.57 |
| SeaStar Medical Holding (ICU) | United States | $0.011B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.010B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.010B | 0.00 |
| KindlyMD (KDLY) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| NewGenIvf Group (NIVF) | Thailand | $0.003B | 0.00 |
| ISpecimen (ISPC) | United States | $0.001B | 0.00 |
| Aclarion (ACON) | United States | $0.000B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |